News light – Alixer Nexgen

Announcements, News & Events

Explore the latest company updates, therapeutic advancements, strategic partnerships, and scientific perspectives shaping the future of translational healthcare innovation.

Alkem licenses technology from Harvard University, aiming to treat ischemic injury and vascular diseases

Alkem Labs gains on exclusive licensing deal with Johns Hopkins University

Alixer Nexgen Successfully Clears U.S. FDA IND for ALDP001 for the Treatment of Seasonal and Perennial Allergic Rhinitis

Advancing the Future of Transformative Therapies

Alixer Nexgen is committed to accelerating scientific innovation through collaboration, translational excellence, and next-generation therapeutic development.